|Bid||21.00 x 900|
|Ask||21.20 x 800|
|Day's Range||21.03 - 21.57|
|52 Week Range||21.03 - 58.72|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.44|
SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2021 / Hagens Berman invites Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) investors with significant losses to submit your losses now.
PHILADELPHIA, PA / ACCESSWIRE / April 15, 2021 / Kaskela Law LLC announces that it is investigating Acadia Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ:ACAD) on behalf of the Company's stockholders.
NEW YORK, NY / ACCESSWIRE / April 14, 2021 / Labaton Sucharow LLP a national securities litigation firm, announces that it is investigating Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) for potential violations of the federal securities laws.